Colchicine and Erythromycin interaction

Colchicine and Erythromycin: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Colchicine label · effective 2026-03-18

Major

Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [see Drug Interactions (7) ] .

Contraindicationsby drug classView label on DailyMed
Major

• Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death ( 5.3 , 7 ).

Warnings and precautionsby drug classView label on DailyMed
Major

Therefore, concomitant use of colchicine capsules and inhibitors of CYP3A4 or P-glycoprotein should be avoided [see Drug Interactions (7) ] .

Warnings and precautionsby drug classView label on DailyMed
Major

Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein.

Drug interactionsby drug classView label on DailyMed
Major

• Concomitant use of colchicine capsules and inhibitors of CYP3A4 or P-gp should be avoided if possible.

Drug interactionsby drug classView label on DailyMed

From the Erythromycin label · effective 2025-09-25

Moderate

These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (for example, verapamil, amlodipine, diltiazem) (see PRECAUTIONS, Drug Interactions ).

Warningsnames ColchicineView label on DailyMed
Moderate

There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine.

Warningsnames ColchicineView label on DailyMed
Moderate

A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin.

Drug interactionsnames ColchicineView label on DailyMed
Moderate

If co-administration of colchicine and erythromycin is necessary, the starting dose of colchicine may need to be reduced, and the maximum colchicine dose should be lowered.

Drug interactionsnames ColchicineView label on DailyMed
Moderate

Patients should be monitored for clinical symptoms of colchicine toxicity (see WARNINGS ).

Drug interactionsnames ColchicineView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.